Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases Life Science Investing
Orthopaedic Institute for Children’s Research May Lead to Treatments for Patients with Rare Bone Disorders Genetics Investing
Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin Biotech Investing
PharmaCyte Biotech Finalizes Design of Pancreatic Cancer Clinical Trial and Identifies Trial Sites under Consideration Biotech Investing
European Medicines Agency Grants Accelerated Assessment of Marketing Authorization Application for Xilonix™, XBiotech’s True Human™ Therapeutic Antibody Treatment for Advanced Colorectal Cancer Biotech Investing
Lipoprotein(a) Foundation Highlights ACC Research Reinforcing the Significance of Lp(a) as a Genetic Risk Factor for Cardiovascular Disease Biotech Investing
Results from Vericel’s Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented Today at ACC and Published in The Lancet Life Science Investing
New Clinical and Pre-Clinical Data Presented at American College of Cardiology Meeting on the Effect of EPA Therapy in Statin-Treated Patients and on Endothelial Function in Exploratory Studies Biotech Investing
Theravance Biopharma to Present New Data Demonstrating Potent in vitro Activity for VIBATIV(R) (telavancin) Against Difficult-to-Treat Infections, Including MRSA, at 2016 ECCMID Conference Life Science Investing
Breathtec Biomedical Provides Update on Lead Project and In-Licensing Discussions Medical Device Investing
SpeeDx Announces Distribution Agreement for PlexPCR(TM) and ResistancePlus(TM) Molecular Diagnostics Products With Goffin Molecular Technologies Medical Device Investing
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026Â
